SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today that David D. Waters, MD has joined the company as Cardiovascular Research Fellow. Dr. Waters has over 20 years of experience in cardiovascular research. His early research involved vasospastic angina, risk stratification in acute coronary syndromes and trials of antiplatelet and antithrombotic therapy for unstable angina. More recently he has directed clinical trials assessing the effect of a calcium channel blocker, statins, antioxidant vitamins and hormone replacement upon the progression of coronary disease, as well as other trials of cholesterol- lowering therapies.
“David clearly brings to Anthera a wealth of knowledge and experience in the areas of cardiovascular research and we are very pleased that he has decided to join our growing team” said Paul F. Truex, President and CEO. “He is a great addition to what is already an excellent team at Anthera, and I know he will contribute significantly to the company’s continued growth and success.”
Dr. David D. Waters, now retired, was Chief of Cardiology at San Francisco General Hospital and the Maurice Eliaser Jr. Distinguished Professor of Medicine at University of California, San Francisco. He completed his medical school at the University of Western Ontario and did his Internal Medicine training at McGill University. After completing his cardiology fellowship training at Emory University, Dr. Waters was appointed as a Canadian Heart Foundation Research Fellow at Cedars-Sinai Medical Center in Los Angeles. Dr. Waters has published over 300 manuscripts, mainly related to coronary artery disease, and has written more than 60 book chapters. He is a member of the editorial boards of several major cardiology journals and was an associate editor of the Journal of the American College of Cardiology.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life-threatening chronic and acute inflammatory diseases. In 2006, Anthera acquired worldwide rights (except Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to address a variety of diseases including: acute chest syndrome, acute lung injury, acute respiratory distress syndrome, atherosclerosis, acute coronary syndrome, chronic obstructive pulmonary disease and psoriasis. In order to efficiently commercialize this platform, Anthera has brought together a proven management team with extensive experience in licensing, clinical research, development, and commercialization of anti-inflammatory products. For more information please visit http://www.anthera.com.
Contact: Press Relations (510) 277-1208 pr@anthera.com
Anthera Pharmaceuticals, Inc.
CONTACT: Press Relations, Anthera Pharmaceuticals, Inc., +1-510-277-1208,or pr@anthera.com
Web site: http://www.anthera.com//
